Tue, February 10, 2009
Mon, February 9, 2009
Sun, February 8, 2009
Fri, February 6, 2009
Thu, February 5, 2009
Wed, February 4, 2009
Tue, February 3, 2009
Mon, February 2, 2009
Sun, February 1, 2009
Sat, January 31, 2009
Fri, January 30, 2009
[ Fri, Jan 30th 2009 ] - Market Wire
Progen-Avexa Merger Update
Thu, January 29, 2009
Wed, January 28, 2009

Sequenom to Hold Fourth Quarter and Full Year 2008 Financial Results Conference Call on February 11


//health-fitness.news-articles.net/content/2009/ .. cial-results-conference-call-on-february-11.html
Published in Health and Fitness on Wednesday, February 4th 2009 at 4:18 GMT, Last Modified on 2009-02-04 04:19:16 by Market Wire   Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic analysis solutions, today announced that it will release fourth quarter and full year 2008 financial results after market close on Wednesday, February 11, 2009. Sequenom management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss those results and answer questions.

Individuals interested in participating in the conference call may do so by dialing (866) 844-2998 for domestic callers, or (706) 679-9912 for international callers. Those interested in listening to the conference call live via the Internet may do so by selecting Investor Relations on the Corporate page of the Company's Web site at [ www.sequenom.com ].

A webcast replay will be available on the Sequenom Web site for 14 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 83065955.

About Sequenom

Sequenom is committed to providing the best genetic analysis products that translate the results of genomic science into solutions for noninvasive prenatal diagnostics, biomedical research, translational research and molecular medicine applications. The Company's proprietary MassARRAY® system is a high-performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. The Company has exclusively licensed intellectual property rights for the development and commercialization of noninvasive prenatal genetic tests for use with the MassARRAY system and other platforms. For more information on Sequenom, please visit the Company's Web site at [ www.sequenom.com ].

Sequenom® and MassARRAY® are trademarks of Sequenom, Inc.


Publication Contributing Sources

Similar Health and Fitness Publications